Cladribine: A review of its use in multiple sclerosis

BioDrugs

Volumn 9, Issue 5, 1998, Pages 419-433

  Langtry, Heather D ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; META ANALYSIS; MULTIPLE SCLEROSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031979137     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809050-00006     Document Type: Review

References (53)

1. Hunter SE, Weinshenker BG, Carter JL, et al. Rational clinical immunotherapy for multiple sclerosis. Mayo Clin Proc 1997 Aug; 72: 765-80
2. Waubant EL, Goodkin DE. Assessing efficacy in clinical trials of treatments for multiple sclerosis: issues and controversy. CNS Drugs 1996 Dec; 6: 462-73
3. Weidbach FX, Hartung H-P. Cladribin in chronic progressive multiple sclerosis [in German]. Nervenarzt 1995 Apr; 66: 299-303
4. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995 Feb; 13 (1): 119-46
5. Antel JP, Arnason BGW. Demyclinating diseases. In: Braunwald E, Isselbacher KJ, Petersdorf KG, et al., editors. Harrison's Principles of Internal Medicine. 11th ed. New York: McGraw-Hill, 1987; 1995-2000
6. Bryson HM, Sorkin EM, Cladribine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993 Nov; 46: 872-94
7. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995 May; 37 Suppl. 1: S87-S101
8. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989; 10 (3): 104-7
9. Spasokoukotskaja T, Arnér ESJ, Brosjö O, et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer A 1995; 31A (2): 202-8
10. Petzer AL, Bilgeri R, Zilian U, et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 1991 Nov 15; 78: 2583-7
11. King KM, Cass CE. Membrane transport of 2-chloro-2′-deoxyadenosine and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine is required for cytotoxicity [abstract]. 85th Annual Meeting of the American Association for Cancer Research 1994 Apr 10: 577
12. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993 Feb 1; 81: 597-601
13. Staub M, Sasvári-Székely M, Spasokukockaja T, et al. 2-Cl-deoxyadenosine increases the activity of deoxycytidine kinase in human lymphocytes [abstract]. Pharm World Sci 1995 Sep 22; 17 Suppl. K: 12
14. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deozyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993 Jan 1; 81: 143-50
15. Gartenhaus RB, Wang P, Hoffman M, et al. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med 1996 Mar; 74: 143-7
16. Idink CAM, Schaafsma MR, Vermes I, et al. 2-Chlorodeoxyadenosine (2CDA) induced apoptosis patients with hairy cell leukemia [abstract]. Proc Am Soc Clin Oncol 1996 Mar; 15: 89
17. Hentosh P, Grippo PJ. 2-Chloroadenine residues in DNA alter binding of DNA polymerase and human transcription factors in vitro [abstract]. 84th Annual Meeting of the American Association for Cancer Research 1993 Mar; 34: 352
18. Henderson DS, Otway RT, Crisp LB, et al. The mechanism of toxicity of 2-chlorodeoxyadenosine against human leukaemias [abstract]. Aust N Z J Med 1996 Apr; 26: 319
19. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996 Feb 20; 93: 1716-20
20. Beutler E, Sipe J, Romine J, et al. The treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996 Jan; 33: 45-52
21. Beutler E, Koziol JA, McMillan R, et al. Marrow suppression produced by repeated doses of cladribine. Acta Haematol 1994; 91: 10-5
22. Grieb P, Stelmasiak Z, Solski J, et al. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Arch Immunol Ther Exp 1995; 43: 323-7
23. Stelmasiak Z, Solski J, Jakubowska B, et al. Safety of cladribine treatment in multiple sclerosis [abstract]. J Neuroimmunol 1995 Suppl. 1: 17
24. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997 Feb; 32: 120-31
25. Albertioni F, Herngren L, Juliusson G, et al. Protein binding of 2-chloro 2′-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia. Eur J Clin Pharmacol 1994; 46 (6): 563-4
26. Ortho Biotech Inc. LeustatinR (cladribine) injection. Prescribing information. Ortho Biotech, Raritan, NJ 08869, USA
27. Leustat injection. In: ABPI compendium of data sheets and summaries of product characteristics. 1996-97 ed. London: Datapharm Publications Limited, 1996; 453-4
28. Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992 Oct; 10: 1514-8
29. Albertioni F, Juliusson G, Liliemark J. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA): metabolism to 2-chloroadenine (CAde) and renal excretion after intravenous and oral administration [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 157
30. Beutler E. Cladribine (2-chlorodeoxyadenosine) [see comments]. Lancet 1992 Oct 17; 340: 952-6
31. Ortho Biotech. Raritan, NJ, USA. Data on file
32. Grieb P, Ryba M, Stelmasiak Z, et al. Cladribine treatment of multiple sclerosis [letter]. Lancet 1994 Aug 20; 344: 538
33. Stelmasiak Z, Solski S, Nowicki J, et al. A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting-relapsing multiple sclerosis. Med Sci Monit 1998; 4(1): 1-5
34. Romine JS, Sipe JC, Koziol JA, et al. Cladribine: use in therapy of multiple sclerosis. Biodrugs 1997 May; 7: 386-93
35. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994 Jul 2; 344: 9-13
36. Rice G, Cladribine Study Group. Cladribine and chronic progressive multiple sclerosis: the results of a multicenter trial [abstract]. Neurology 1997 Jun; 48: 1730
37. Bekiesinska-Figatowska M, Walecki J, Stelmasiak Z. The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis. Acta Neurobiol Exp Warsz 1996; 56: 171-6
38. Beutler E, Sipe JC, Romine JS, et al. Cladribine therapy for chronic progressive and relapsing/remitting multiple sclerosis [abstract]. J Invest Med 1997 Mar; 45: 287A
39. Koziol JA, Frutos A, Sipe JC, et al. A comparison of two neurologic scoring instruments for multiple sclerosis. J Neurol 1996 Mar; 243: 209-13
40. Polman CH, Hartung H-P. The treatment of multiple sclerosis: current and future. Curr Op Neurol Neurosurg 1995 Jun; 8: 200-9
41. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16
42. Lublin FD, Reingold SC. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Muliple Sclerosis. Guidelines tor clinical trials of new therapeutic agents in multiple sclerosis. Relations between study investigators, advisors, and sponsors. Neurology 1997 Mar; 48: 572-4
43. Baltz JK, Montello MJ. Cladribine for the treatment of hematologic malignancies. Clin Pharm 1993 Nov; 12: 805-13
44. Sipe JC, Romine JS, Koziol JA, et al. Development of cladribine treatment in multiple sclerosis. Multiple Sclerosis 1996 Jul; 1 (6): 343-7
45. Saven A, Kawasaki H, Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 1993 Apr; 11: 671-8
46. Reid JM, Bagniewski PG, Richardson RL, et al. Clinical pharmacology of 2-chlorodeoxy-adenosine in patients with solid tumors, chronic leukemia or lymphoma [abstract]. Ann Oncol 1994; 5 Suppl. 5: 174
47. Polman CH, Koetsier JC. Cladribine treatment of multiple sclerosis [letter]. Lancet 1994 Aug 20; 344: 537
48. Sipe J, Koziol J, Romine J, et al. Cladribine treatment of multiple sclerosis. Reply [letter]. Lancet 1994 Aug 20; 344: 537-8
49. Ebers GC. Treatment of multiple sclerosis. Lancet 1994 Jan 29; 343: 275-9
50. Holliday SM, Benfield P. Interferon-β-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Biodrugs 1997 Oct; 8: 317-30
51. Ebers G, Paty DW, Oger J, et al. The PRISMS study: prevention of relapses and disability by interferon-beta 1a, Rebif®, subcutaneously in multiple sclerosis [poster], 13th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Istanbul, Turkey. 2-5 Nov, 1997
52. Faulds D, Benfield P. Interferon beta-1b in multiple sclerosis. An initial review of its rationale for use and therapeutic potential. Clin Immunother 1994 Jan; 1: 79-87
53. Lea AP, Goa KL. Copolymer-1: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Clin Immunother 1996 Oct; 6: 319-31